IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	pplicat	ion of:					
Dario l	NERI e	t al.	Examiner: Virginia Allen Portner				
Serial	No.: 10	/821,930	Group Art Unit: 1645				
Filed:	April 12	2, 2004	Confirmation No.: 3681				
CONT	Citle: SPECIFIC BINDING MOLECULES FOR SCINTIGRAPHY, CONJUGATES CONTAINING THEM AND THERAPEUTIC METHOD FOR TREATMENT OF ANGIOGENESIS						
INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98							
P.O. B	ox 1450	r for Patents O A 22313-1450					
Sir:							
This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:							
Timing	g and Fo	ees					
		37 C.F.R. § 1.97(b), no fee or statement is required for filing this information sure statement is filed:					
		within three months of the filing dat under § 1.53(d);	te of a national application other than a CPA				
		within three months of the actual application; OR	filing date of the national phase of a PCT				
		before the mailing of a first substant RCE).	tive office action (including after filing of an				
\boxtimes	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:						
		a final rejection under 37 C.F.R. 1.1 termination of prosecution, e.g. Ex a notice of allowance under 37 C.F.	Parte Quayle, M.P.E.P § 609(B)(2); OR				

		is accompanied by:			
			the statement as specified in 37 C.F.R. § 1.97(e) set out below;		
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or		
		\boxtimes	payment by credit card via EFS covering the fee of \$180.00 under 37 C.F.R. \S 1.17(p); or		
	Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailidate of the following actions which have not been withdrawn:				
		a final	action under 37 C.F.R. § 1.113;		
	termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);				
	OR a notice of allowance under 37 C.F.R. § 1.311;				
	AND is filed on or before payment of the issue fee; AND is accompanied by:				
	the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).				
<u>Statem</u>	ents Ur	nder 37	C.F.R. 1.97(e)		
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or		
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.		
Cited N	<u>Materia</u>	<u>ls</u>			
		ancesto	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).		
		_	s of materials listed but not attached were cited in an international search dated		

[Not required by 37 CFR § 1.98.		
l	\boxtimes	Copies of the materials listed are attached (except for the foregoing).		
Non-En	glish L	anguage References		
[An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).		
[A foreign-language search report from a foreign patent office is provided, an pertinent parts are translated substantively below:		
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art O = non-written disclosure P = intercalated document T = document cited to understand the theory or principle underlying the invention E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date D = cited in the application L = cited for another reason & = publication of member of same patent family Translation of other relevant information on foreign search report 		
Other In	nforma	<u>tion</u>		
		es Due (If Any): k for \$ covering the fee identified above is attached.		
	Payment by credit card via EFS for \$180.00 covering the fee identified above.			
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.		

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402.

Respectfully submitted,

/Anthony J. Zelano/

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: ELLIS-0002-P02-C01

Date: March 10, 2010

AJZ:klb